ArticleHeart rhythm O22025
Clinical outcomes after ventricular tachycardia ablation with or without induction.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of left ventricular ejection fraction on clinical outcomes following ventricular tachycardia ablation: a propensity-matched analysis from a large multicentre database.European heart journal open · 2026Article
- Safety of ventricular tachycardia ablation under deep sedation with propofol and fentanyl.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Substrate mapping may offer a safer alternative to ventricular tachycardia (VT) mapping by avoiding prolonged episodes of VT during catheter ablation. However, VT induction to gauge procedural efficacy is still routinely attempted following substrate ablation, thereby exposing patients to potentially unnecessary hemodynamic risk. Objective: The purpose of this study was to assess the efficacy of VT ablation without VT induction. Methods: Patients with implantable cardioverter-defibrillators who underwent VT ablation between August 2020 and May 2023 were assessed retrospectively. Ablation and induction strategies were determined by operator discretion. Patients with or without attempted VT induction were compared with respect to baseline characteristics and clinical outcomes using Cox and competing risks regression. Results: Eighty-nine patients (median age 68 years; 89% male; 51% infarct-related cardiomyopathy, mean left ventricular ejection fraction 38%) were followed for a median of 16 months after VT ablation. VT induction was attempted in 63% of patients. The 1-year incidence of recurrent VT was 37% and 58% in the noninduction and induction groups, respectively (subhazard ratio 0.55, 95% confidence interval [CI] 0.27-1.09, Conclusion: In a single-center study of 89 VT ablations, a noninduction strategy was similar to an induction strategy with respect to VT recurrence, heart transplant, or death at 1 year. Our findings suggest that VT induction, recognized as a risk factor for hemodynamic compromise, can be avoided in some patients without sacrificing procedural efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.